Document is current
Any future updates will be listed below
-
Authors
Messmer, Anna S. https://orcid.org/0000-0002-3206-9112
Pitteloud, Matthieu
Quintard, Hervé
Pietsch, Urs
Müller, Martin
Filipovic, Miodrag
Jakob, Stephan M.
Z’Graggen, Werner J.
Schefold, Joerg C.
Pfortmueller, Carmen A.
-
Funding
Funding for this research was provided by:
OPO-Stiftung (2020-0013)
Anaesthesiology and Intensive Care Foundation, Bern (22/2020)
Departement für Lehre und Forschung, University Hospital Bern, Inselspital (4889)
- License Information
-
More Information
Article History
Received: 1 February 2025
Accepted: 22 August 2025
First Online: 17 October 2025
Declarations
:
: The CrystallBrain trial has been approved from the lead ethical committee of the Canton Bern (No. 2019-00492) and from the ethical committee of the Canton Geneva (same number). The decision of the ethical committee of the Canton St. Gallen is currently pending. Individual consent will be sought from all trial participants (see online supplemental).
: A model consent form (German and French version only) is available on request from the corresponding author.
: Messmer AS, Pitteloud M, Schefold JC, and Pfortmueller CA are affiliated with the Department of Intensive Care, University Hospital, Inselspital, which reports grants from Orion Pharma, Abbott Nutrition International, B. Braun Medical AG, CSEM AG, Edwards Lifesciences Services GmbH, Kenta Biotech Ltd, Maquet Critical Care AB, Omnicare Clinical Research AG, Nestlé, Pierre Fabre Pharma AG, Pfizer, Bard Medica S.A., Abbott AG, Anandic Medical Systems, Pan Gas AG Healthcare, Bracco, Hamilton Medical AG, Fresenius Kabi, Getinge Group Maquet AG, Dräger AG, Teleflex Medical GmbH, GlaxoSmithKline, Merck Sharp and Dohme AG, Eli Lilly and Company, Baxter, Astellas, AstraZeneca, CSL Behring, Novartis, Covidien, Phagenesis, Cytel, and Nycomed outside the project. The money was paid into departmental funds; no personal financial gain applied. All other authors have nothing to disclose.
